

Cardiovascular Recommendation Tables

Current as of:
February, 2009

The first publication of the Cardiovascular Recommendation Tables occurred in the October 2002, **Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers**, FMCSA-MCP-02-002.

[PDF Version](#) - [HTML Version](#)

Effort has been made to ensure the accuracy of data conversion when creating these tables. Please [Contact NRCME](#) if you identify an issue.

Important Note: If you print the tables, you should periodically verify that the print file is current with the last update posted on the NRCME Web site at:

http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.

See the Cardiovascular Table Archives for descriptions of the updates. A log of changes made is posted on the NRCME Web site, on the Cardiovascular Table Archives Web page located at

http://nrcme.fmcsa.dot.gov/cvs_tables_archive.htm.

Preface

The Federal Motor Carrier Safety Administration (FMCSA) has an ongoing process for reviewing all Federal medical standards and guidelines used to determine driver medical fitness for duty.

These tables will be updated when changes are made to FMCSA medical standards and guidelines. All proposed changes to the medical standards are subject to public notice-and-comment rulemaking.

As part of its review process, FMCSA considers medical evidence reports, medical expert panel (MEP) opinion, and Medical Review Board (MRB) recommendations. FMCSA also considers other factors such as feasibility and impact.

These tables do not include recommendations that have been submitted to FMCSA for consideration but not adopted by FMCSA. However, FMCSA posts copies of the medical evidence report executive summaries and MEP recommendations on the FMCSA Web page Reports - How Medical Conditions Impact Driving found at <http://www.fmcsa.dot.gov/rules-regulations/topics/mep/mep-reports.htm>.

Reports of MRB proceedings are posted on the MRB Web site at <http://www.mrb.fmcsa.dot.gov/proceedings.htm>, and the MRB public meeting schedule at http://www.mrb.fmcsa.dot.gov/meetings_scheduled.htm.

Medical examiners may submit questions or comments to the FMCSA Office of Medical Programs by sending an email to fmcsamedical@dot.gov.

Table of Contents

Cardiovascular Recommendation Tables	1
Preface.....	2
Table of Contents.....	3
ANEURYSMS.....	4
AORTIC CONGENITAL HEART DISEASE.....	5
AORTIC CONGENITAL HEART DISEASE (Continued).....	6
AORTIC REGURGITATION.....	7
AORTIC STENOSIS.....	8
ATRIAL SEPTAL DEFECTS.....	9
ATRIAL SEPTAL DEFECTS (Continued).....	10
ATRIAL SEPTAL DEFECTS (Continued).....	11
BUNDLE BRANCH BLOCKS AND HEMIBLOCKS.....	12
CARDIOMYOPATHIES AND CONGESTIVE HEART FAILURE (CHF).....	13
COMMERCIAL DRIVERS WITH KNOWN CORONARY HEART DISEASE (CHD).....	14
COMMERCIAL DRIVERS WITH KNOWN CORONARY HEART DISEASE (CHD) (Continued).....	15
COMMERCIAL DRIVERS WITHOUT KNOWN CORONARY HEART DISEASE (CHD).....	16
CONGENITAL HEART DISEASE.....	17
CONGENITAL HEART DISEASE (Continued).....	18
CONGENITAL HEART DISEASE (Continued).....	19
CONGENITAL HEART DISEASE (Continued).....	20
CONGENITAL HEART DISEASE (Continued).....	21
HEART TRANSPLANTATION.....	22
HYPERTENSION.....	23
IMPLANTABLE DEFIBRILLATORS.....	24
MITRAL REGURGITATION.....	25
MITRAL STENOSIS.....	26
PACEMAKERS.....	27
PACEMAKERS (Continued).....	28
PACEMAKERS (Continued).....	29
PERIPHERAL VASCULAR DISEASE.....	30
SUPRAVENTRICULAR TACHYCARDIAS.....	31
SUPRAVENTRICULAR TACHYCARDIAS (Continued).....	32
VALVE REPLACEMENT.....	33
VALVE REPLACEMENT (Continued).....	34
VENOUS DISEASE.....	35
VENTRICULAR ARRHYTHMIAS.....	36
VENTRICULAR ARRHYTHMIAS (Continued).....	37
VENTRICULAR SEPTAL DEFECTS.....	38

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

ANEURYSMS

2002 Cardiovascular Conference Report Recommendation Tables, Page 145

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Abdominal Aortic Aneurysm (AAA)	Evaluate for associated cardiovascular diseases.		
	Aneurysm <4.0 cm.	Yes, if asymptomatic.	Annual
	Aneurysm 4.0 to <5.0 cm. Ultrasound to identify change in size.	Yes if: Asymptomatic; Cleared by vascular specialist. No, if: Symptomatic; Surgery recommended by vascular specialist.	Annual Ultrasound for change in size.
	Aneurysm >5.0 cm.	Yes if: At least 3 months after surgical repair; Cleared by cardiovascular specialist. No. Yes if: At least 3 months after surgical repair; Cleared by cardiovascular specialist.	Annual Annual
Thoracic Aneurysm	Evaluate for associated cardiovascular diseases.	No, if >3.5 cm. Yes if: At least 3 months after surgical repair; Cleared by cardiovascular specialist.	Annual
Aneurysms of Other Vessels	Assess for risk of rupture and for associated cardiovascular diseases.	No Yes if: At least 3 months after surgical repair; Cleared by cardiovascular specialist.	Annual

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

AORTIC CONGENITAL HEART DISEASE

2002 Cardiovascular Conference Report Recommendation Tables, Page 122

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Bicuspid Aortic Valve	May result in aortic stenosis or regurgitation (see section on Valvular Diseases), aortic root enlargement, aortic aneurysm formation and aortic rupture.	See section on Valvular Diseases. No if: Aortic transverse diameter >5.5 cm. Yes if: Surgical intervention successfully performed.	See section on Valvular Diseases. Annual
Subvalvular Aortic Stenosis	Mild = favorable. Has potential for progression. Moderate or severe = unfavorable.	Yes if: Aortic; No valvular abnormality or hypertrophic cardiomyopathy. No if: Symptomatic and mean pressure gradient >30 mm Hg. Yes if: At least 3 months after successful surgical resection when cleared by cardiologist knowledgeable in congenital heart disease.	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease is required. Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease required, including echocardiogram.
Discrete Supravalvular Aortic Stenosis	Unfavorable prognosis due to associated coronary and aortic disorder.	No, unless surgery. Yes if: At least 3 months post-surgical intervention; Cleared by cardiologist knowledgeable in adult congenital heart disease.	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease is recommended.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

AORTIC CONGENITAL HEART DISEASE (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 123

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Marfan Syndrome	Cardiovascular disorders are the major cause of morbidity and mortality including risk of sudden death.	Yes if: No cardiovascular involvement. No if: Any aortic root enlargement; Moderate or more severe aortic regurgitation; > mild mitral regurgitation related to mitral valve prolapse; LV dysfunction with EF <40% and no associated valve disease.	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease required including aortic root imaging and echocardiography.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

AORTIC REGURGITATION

2002 Cardiovascular Conference Report Recommendation Tables, Page 79

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Mild Aortic Regurgitation		Yes, if asymptomatic.	Annual Echocardiogram every 2 to 3 years.
Moderate Aortic Regurgitation		Yes, if: Normal LV function; No or mild LV enlargement.	Annual Echocardiogram every 2 to 3 years.
Severe Aortic Regurgitation		Yes if: Asymptomatic; Normal LV function (EF = 50%); LV dilatation (LVEDD <60mm, LVESD <50mm). If LVEDD = 60mm or LVESD = 50mm. No if: Symptoms; Unable to complete Bruce protocol Stage II; Reduced EF <50%, LV dilatation LVEDD >70mm or LVESD >55mm. Yes if: Valve surgery and at least 3 months post surgery; Asymptomatic; Cleared by cardiologist.	Every 6 months Echocardiogram every 6 to 12 months. Every 4–6 months Echocardiogram every 4–6 months if no surgery performed. Annual

EF=Ejection fraction

LVESD=Left ventricular end-systolic dimension

LVEDD=Left ventricular end-diastolic dimension

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

AORTIC STENOSIS

2002 Cardiovascular Conference Report Recommendation Tables, Page 78

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Mild Aortic Stenosis (AVA >1.5 cm ²)	If symptoms are consistent with aortic stenosis but calculated valve area suggests mild aortic stenosis, the severity of the stenosis and an alternative explanation for symptoms needs to be reassessed.	Yes, if Asymptomatic.	Annual Echocardiogram every 5 years.
Moderate Aortic Stenosis (AVA ≥1.0-1.5 cm ²)		Yes, if: Asymptomatic; Yes if: At least 3 months after surgery. No if: Angina, heart failure, syncope; Atrial fibrillation; LV dysfunction with EF <50%; Thromboembolism.	Annual Echocardiogram every 1 to 2 years. Annual
Severe Aortic Stenosis (AVA <1.0 cm ²)		No, irrespective of symptoms or LV function. Yes, if at least 3 months after surgery.	Annual

AVA = aortic valve area

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

ATRIAL SEPTAL DEFECTS

2002 Cardiovascular Conference Report Recommendation Tables, Page 124

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION RECOMMENDATION	CERTIFICATION
Atrial Septal Defect (ASD): Ostium Secundum	<p>Small ASD = favorable.</p> <p>Moderate to large ASD = unfavorable.</p>	<p>Yes if: Asymptomatic.</p> <p>No if: Symptoms of dyspnea, palpitations or a paradoxical embolus; Pulmonary hypertension; Right-to-left shunt; Pulmonary to systemic flow ratio >1.5 to 1.</p> <p>Yes if: At least 3 months after surgery or at least 4 weeks after device closure; Asymptomatic and clearance by cardiologist knowledgeable in adult congenital heart disease.</p>	<p>Annual Evaluation by cardiologist knowledgeable in congenital heart disease including echocardiogram.</p> <p>Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease every 2 years.</p>

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

ATRIAL SEPTAL DEFECTS (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 125

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
ASD: Ostium Primum	<p>Small ASD = favorable prognosis.</p> <p>Moderate to large ASD = unfavorable prognosis.</p>	<p>Yes if: Asymptomatic.</p> <p>No if: Symptoms of dyspnea, palpitations or a paradoxical embolus; Echo-Doppler demonstrates pulmonary artery pressure >50% systemic; Echo-Doppler demonstrates right-to-left shunt; Pulmonary to systemic flow ratio greater than 1.5 to 1; Heart block on an electrocardiogram; More than mild mitral valve regurgitation; Left ventricular outflow tract obstruction with a gradient >30 mm Hg.</p> <p>Yes if: At least 3 months after surgical intervention if none of the above disqualifying criteria; No symptomatic arrhythmia and no significant residual shunt; Cleared by cardiologist knowledgeable in adult congenital heart disease.</p>	<p>Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease required including echocardiogram.</p> <p>Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease.</p>

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

ATRIAL SEPTAL DEFECTS (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 126

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Sinus Venous Atrial Septal Defect	Usually associated with anomalous pulmonary venous connection. Prognosis depends on size of atrial septal defect. Commonly associated with sinus node dysfunction, particularly after surgery.	<p>Yes if: Small shunt and hemodynamically insignificant.</p> <p>No if: Symptoms of dyspnea, palpitations or a paradoxical embolus; Echo-Doppler examination demonstrating pulmonary artery pressure greater than 50% systemic; Echo-Doppler examination demonstrating a right-to-left shunt; Pulmonary to systemic flow ratio greater than 1.5 to 1; Heart block or sinus node dysfunction on an electrocardiogram.</p> <p>Yes if: At least 3 months after surgical intervention; Hemodynamics are favorable; Cleared by cardiologist knowledgeable in adult congenital heart disease.</p>	<p>Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease.</p> <p>Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease, including Holter Monitor.</p>

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

CARDIOMYOPATHIES AND CONGESTIVE HEART FAILURE (CHF)

2002 Cardiovascular Conference Report Recommendation Tables, Page 82

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Hypertrophic Cardiomyopathy		No.	
Idiopathic Dilated Cardiomyopathy and Congestive Heart Failure		No, if symptomatic CHF.	
		No if: Asymptomatic; Ventricular arrhythmias present; LVEF \leq 50%.	
		No if: Asymptomatic; No ventricular arrhythmias; LVEF <40%.	
		Yes if: Asymptomatic; No ventricular arrhythmias; LVEF 40% to 50%.	Annual Requires annual cardiology evaluation including Echocardiography and Holter monitoring.
Restrictive Cardiomyopathy		No	

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

**COMMERCIAL DRIVERS WITH KNOWN CORONARY HEART DISEASE
(CHD)**

2002 Cardiovascular Conference Report Recommendation Tables, Page 36

DIAGNOSIS	PHYSIOLOGIC/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Post Myocardial Infarction (MI)	Risk of recurrent major cardiac event highest within the first months post-MI. Drivers in a rehabilitation program can receive comprehensive secondary prevention therapy.	No if: Recurrent angina symptoms; Post-MI ejection fraction <40% (by echocardiogram or ventriculogram); Abnormal ETT demonstrated prior to planned work return; Ischemic changes on rest ECG; Poor tolerance to current cardiovascular medications. Yes if: At least 2 months post-MI; Cleared by cardiologist; No angina; Post-MI ejection fraction ≥40% (by echocardiogram or ventriculogram); Tolerance to current cardiovascular medications.	Annual Biennial ETT at minimum (If test positive or inconclusive, imaging stress test may be indicated). Cardiologist examination recommended.
Angina Pectoris	Lower end of spectrum among CHD patients for risk of adverse clinical outcomes. Condition usually implies at least one coronary artery has hemodynamically significant narrowing.	Yes, if asymptomatic. No if: Rest angina or change in angina pattern within 3 months of examination; Abnormal ETT; Ischemic changes on rest ECG; Intolerance to cardiovascular therapy.	Annual Biennial ETT at minimum (If test positive or inconclusive, imaging stress test may be indicated). Cardiologist examination recommended.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

**COMMERCIAL DRIVERS WITH KNOWN CORONARY HEART DISEASE
(CHD) (Continued)**

2002 Cardiovascular Conference Report Recommendation Tables, Page 37

DIAGNOSIS	PHYSIOLOGIC/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Post Percutaneous Coronary Intervention (PCI)	Rapid recovery for elective PCIs for stable angina. Delayed re-stenosis is the major PCI limitation and requires intensive secondary prevention.	Yes if: At least 1 week after procedure; Approval by cardiologist; Tolerance to medications. ETT 3 to 6 months after PCI. No if: Incomplete healing or complication at vascular access site; Rest angina; Ischemic ECG changes.	Annual Recommend cardiologist examination. Biennial ETT at minimum (If test positive or inconclusive, imaging stress test may be indicated).
Post Coronary Artery Bypass Surgery (CABG)	Delay in return to work to allow sternal incision healing. Because of increasing risk of graft closure over time, ETT is obtained.	Yes if: At least 3 months after CABG; LVEF \geq 40% post CABG; Approval by cardiologist; Asymptomatic; Tolerance to medications.	Annual After 5 years: Annual ETT. Imaging stress test may be indicated.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

COMMERCIAL DRIVERS WITHOUT KNOWN CORONARY HEART DISEASE (CHD)

2002 Cardiovascular Conference Report Recommendation Tables, Page 35

DIAGNOSIS	PHYSIOLOGIC/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Asymptomatic, healthy	Low CHD event risk. Assess for clinically apparent risk factors. Use, when possible, Framingham risk score model to predict 10-year CHD event risk. Increasing age is a surrogate marker for increasing atherosclerotic plaque burden.	Yes, if asymptomatic; Rarely disqualifying alone.	Biennial
Asymptomatic, high risk person (as designated by CHD risk-equivalent condition)* Asymptomatic, high risk person >45 years with multiple risk factors for CHD	Sub-clinical coronary atherosclerosis is a concern. High-risk status requires close physician follow-up and aggressive comprehensive risk factor management.	Yes if: asymptomatic. No if: Abnormal ETT;** Ischemic changes on ECG;† Functional incapacitation by one of conditions.	Annual

*CHD risk equivalent is defined as presence of diabetes mellitus, peripheral vascular disease, or Framingham risk score predicting a 20% CHD event risk over the next 10 years.

** Abnormal Exercise Tolerance Test (ETT) is defined by an inability to exceed 6 METS (beyond completion of Stage II, or 6 minutes) on a standard Bruce protocol or the presence of ischemic symptoms and/or signs (e.g., characteristic angina pain or 1 mm ST depression or elevation in 2 or more leads), inappropriate SBP and/or heart rate responses (e.g., inability in the maximal heart rate to meet or exceed 85% of age-predicted maximal heart rate), or ventricular dysrhythmia.

† Ischemic ECG changes are defined by the presence of new 1 mm ST-segment elevation or depression and/or marked T wave abnormality.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

CONGENITAL HEART DISEASE

2002 Cardiovascular Conference Report Recommendation Tables, Page 128

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Patent Ductus Arteriosus (PDA)	Small = favorable. Moderate to large = unfavorable	Yes, if small shunt. No if: Symptoms of dyspnea or palpitations; Pulmonary hypertension; Right to left shunt; Progressive LV enlargement or decreased systolic function. Yes if: At least 3 months after surgery or 1 month after device closure; None of above disqualifying criteria; Cleared by cardiologist knowledgeable in adult congenital heart disease.	Annual Annual Should have evaluation by cardiologist knowledgeable in adult congenital heart disease.
Coarctation of the Aorta	Mild = favorable. Moderate or severe = unfavorable prognosis.	Yes if: Mild and unoperated; BP controlled; No associated disqualifying disease. No	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease recommended.
Coarctation of the Aorta after intervention	Unfavorable prognosis with persistent risk of cardiovascular events.	Yes, if perfect repair (see text p. 115 and 116).	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease required.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

CONGENITAL HEART DISEASE (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 130

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RE-CERTIFICATION
Ebstein Anomaly	Mild = favorable. Moderate and severe variants = unfavorable.	Yes if: Mild; Asymptomatic; No intracardiac lesions; No shunt; No symptomatic arrhythmia or accessory conduction; Only mild cardiac enlargement; Only mild RV dysfunction. No if: (see text, p. 117). Yes if: At least 3 months post-surgical intervention; None of above disqualifying features.	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease. Annual Echocardiogram and evaluation by cardiologist knowledgeable in adult congenital heart disease required.
Tetralogy of Fallot	Unfavorable in the unrepaired state. Repaired = variable prognosis.	No, if uncorrected. Yes if: Excellent result obtained from surgery; Asymptomatic; No significant pulmonary or tricuspid valve regurgitation; No pulmonary stenosis; No history of arrhythmias; No residual shunt.	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease required, including EKG, 24-hour Holter Monitor, exercise testing, Doppler Echocardiogram.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

CONGENITAL HEART DISEASE (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 131

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Transposition of the Great Vessels	Unfavorable if uncorrectable.	No	Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease.
	Atrial switch repair (Mustard or Senning procedures). Unfavorable long-term prognosis.	No	
	After Rastelli repair.	Yes if: Asymptomatic and excellent result obtained from surgery No if: (see text p.119).	
	After arterial switch repair, prognosis appears favorable.	No (Data currently not sufficient to support qualification in this group).	

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

CONGENITAL HEART DISEASE (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 132

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Congenitally Corrected Transposition	95% have associated intracardiac lesions. Conduction system is inherently abnormal.	<p>Yes if: None of below disqualifying criteria.</p> <p>No if: Symptoms of dyspnea, palpitations, syncope or paradoxical embolus; Intracardiac lesion such as VSD; >moderate pulmonary stenosis with a pulmonary ventricular pressure >50% systemic; >mild RV or LV enlargement or dysfunction; Moderate or greater tricuspid valve (systemic atrioventricular valve) regurgitation; History of atrial or ventricular arrhythmia; ECG with heart block; Right-to-left shunt or significant residual left-to-right shunt.</p> <p>Yes if: At least 3 months after surgery; None of above disqualifying criteria; Prosthetic valve—must meet requirements for that valve; Cleared by cardiologist knowledgeable in adult congenital heart disease.</p>	<p>Annual Required annual evaluation by cardiologist knowledgeable in adult congenital heart disease includes echocardiography and 24-hour Holter Monitor.</p> <p>Annual Evaluation by cardiologist knowledgeable in adult congenital heart disease.</p>

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

HEART TRANSPLANTATION

2002 Cardiovascular Conference Report Recommendation Tables, Page 154

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Heart Transplantation	Special attention to: Accelerated atherosclerosis, transplant rejection, general health.	Yes if: At least 1 year post-transplant; Asymptomatic; Stable on medications; No rejection; Consent from cardiologist to drive commercially.	Biannual Clearance by cardiologist required.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

HYPERTENSION

2002 Cardiovascular Conference Report Recommendation Tables, Page 55

DIAGNOSIS	PHYSIOLOGIC/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Essential Hypertension	Evaluate for other clinical CVD including TOD.† Presence of TOD, CVD or diabetes may affect therapy selected.	Yes, if asymptomatic. Rarely disqualifying alone.	Biennial
Stage 1 (140-159/90-99 mm Hg)	Usually asymptomatic. Low risk for near-term incapacitating event.	Yes Rarely disqualifying alone.	Annual BP <140/90 at annual exam. If not, but <160/100, certification extended one time for 3 months.
Stage 2 (160–179/100–109 mm Hg)	Low risk for incapacitating event. Risk increased in presence of TOD. Indication for pharmacologic therapy.	Yes One time certification for 3 months. Yes, at recheck if: BP ≤140/90 mm Hg; Certify for 1 year from date of initial exam.	Annual BP ≤140/90.
Stage 3 (≥180/110 mm Hg)	High risk for acute hypertension-related event.	No Immediately disqualifying. Yes, at recheck if: BP ≤140/90 mm Hg; Treatment is well tolerated; Certify for 6 months from date of initial exam.	Every 6 months BP ≤140/90.
Secondary Hypertension	Evaluation warranted if persistently hypertensive on maximal or near-maximal doses of 2-3 pharmacologic agents. May be amenable to surgical/specific therapy.	Based on above stages. Yes if: Stage 1 or nonhypertensive; At least 3 months after surgical correction.	Annual BP ≤140/90.

† TOD – Target Organ Damage – Heart Failure, Stroke or Transient Ischemic Attack, Peripheral Artery Disease, Retinopathy, Left Ventricular Hypertrophy, Nephropathy. Examiner may disqualify a driver if TOD significantly impairs driver’s work capacity. Driver should have no excess sedation or orthostatic change in BP.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

IMPLANTABLE DEFIBRILLATORS

2002 Cardiovascular Conference Report Recommendation Tables, Page 104

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Primary Prevention	Patient has high risk for death and sudden incapacitation.	No	
Secondary Prevention	Patient demonstrated to have high risk for death and sudden incapacitation.	No	

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

MITRAL REGURGITATION

2002 Cardiovascular Conference Report Recommendation Tables, Page 77

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Mild Mitral Regurgitation		Yes, if: Asymptomatic; Normal LV size and function;* Normal PAP.	Annual Annual echo not necessary.
Moderate Mitral Regurgitation		Yes, if: Asymptomatic; Normal LV size and function;* Normal PAP.	Annual Annual Echocardiogram.
Severe Mitral Regurgitation		Yes, if asymptomatic. Yes if: At least 3 months post-surgery; Asymptomatic; Cleared by cardiologist. No if: Symptomatic; Inability to achieve >6 METS on Bruce protocol; Ruptured chordae or flail leaflet; Atrial fibrillation; LV dysfunction;* Thromboembolism; Pulmonary artery pressure >50% of systolic arterial pressure.	Annual Echocardiogram every 6-12 months. Exercise testing may be helpful to assess symptoms. Annual

EF = Ejection fraction; LVESD = Left ventricular end-systolic dimension

LVEDD = Left ventricular end-diastolic dimension;

PAP = Pulmonary artery pressure

*Measures include: LVEF <60%; LVESD ≥45mm; LVEDD ≥70mm

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

MITRAL STENOSIS

2002 Cardiovascular Conference Report Recommendation Tables, Page 76

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
*Mild Mitral Stenosis MVA $\geq 1.6 \text{ cm}^2$	In the presence of symptoms consistent with moderate to severe mitral stenosis but a calculated valve area suggesting mild mitral stenosis, the severity of the stenosis should be reassessed and an alternative explanation for symptoms should be considered.	Yes, if asymptomatic.	Annual
*Moderate Mitral Stenosis MVA 1.0 to 1.6 cm^2		Yes, if asymptomatic.	Annual
*Severe Mitral Stenosis MVA $\leq 1.0 \text{ cm}^2$		No if: NYHA Class II or higher; Atrial fibrillation; Pulmonary artery pressure $> 50\%$ of systemic pressure; Inability to exercise for > 6 Mets on Bruce protocol (Stage II). Yes if: At least 4 weeks post percutaneous balloon mitral valvotomy; At least 3 months post surgical commissurotomy; Clearance by cardiologist.	Annual Annual evaluation by a cardiologist.

MVA = mitral valve area

*See text p.61 for additional echocardiogram criteria.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

PACEMAKERS

2002 Cardiovascular Conference Report Recommendation Tables, Page 101

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION RE	CERTIFICATION
Sinus Node Dysfunction	Variable long-term prognosis depending on underlying disease, but cerebral hypoperfusion corrected by support of heart rate by pacemaker.	No Yes if: 1 month after pacemaker implantation; Documented correct function by pacemaker center; Underlying disease is not disqualifying.	Annual Documented pacemaker checks.
Atrioventricular (AV) Block	Variable long-term prognosis depending on underlying disease, but cerebral hypoperfusion corrected by support of heart rate by pacemaker.	No Yes if: 1 month after pacemaker implantation and documented correct function by pacemaker center; Underlying disease is not disqualifying.	Annual Documented pacemaker checks.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

PACEMAKERS (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 102

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION RE	CERTIFICATION
Neurocardiogenic Syncope	Excellent long-term survival prognosis, but there is risk for syncope that may be due to cardioinhibitory (slowing heart rate) or vasodepressor (drop in blood pressure) components, or both. Pacemaker will affect only cardioinhibitory component, but will lessen effect of vasodepressor component.	No, with symptoms. Yes if: 3 months* after pacemaker implantation; Documented correct function by pacemaker center; Absence of symptom recurrence.	Annual Documented pacemaker checks. Absence of symptom recurrence.

*Three months recommended due to possible vasodepressor component of syndrome not necessarily treated by pacing.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

PACEMAKERS (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 103

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Hypersensitive Carotid Sinus with Syncope	Excellent long-term survival prognosis, but there is risk for syncope that may be due to cardioinhibitory (slowing heart rate) or vasodepressor (drop in blood pressure) components, or both. Pacemaker will affect only cardioinhibitory component, but will lessen effect of vasodepressor component.	No, with symptoms. Yes if: 3 months* after pacemaker implantation; Documented correct function by pacemaker center; Absence of symptom recurrence.	Annual Documented regular pacemaker checks. Absence of symptom recurrence.

*Three months recommended due to possible vasodepressor component of syndrome not necessarily treated by pacing.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

PERIPHERAL VASCULAR DISEASE

2002 Cardiovascular Conference Report Recommendation Tables, Page 146

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Peripheral Vascular Disease (PVD)	Evaluate for associated cardiovascular diseases.	Yes, if no other disqualifying cardiovascular condition.	Annual
Intermittent Claudication	Most common presenting manifestation of occlusive arterial disease.	Yes if: At least 3 months after surgery; Relief of symptoms; No other disqualifying cardiovascular disease.	Annual
	Rest pain.	No, if symptoms. Yes if: At least 3 months after surgery; Relief of symptoms and signs; No other disqualifying cardiovascular disease.	Annual

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

SUPRAVENTRICULAR TACHYCARDIAS

2002 Cardiovascular Conference Report Recommendation Tables, Page 96

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Atrial Fibrillation			
Lone Atrial Fibrillation	Good prognosis and low risk for stroke.	Yes	Annual
Atrial fibrillation as cause of or a risk for stroke	Risk for stroke decreased by anticoagulation.	Yes if: Anticoagulated adequately for at least 1 month; Anticoagulation monitored by at least monthly INR; Rate/rhythm control deemed adequate (Recommend assessment by cardiologist).	Annual
Atrial fibrillation following thoracic surgery	Good prognosis and duration usually limited.	In atrial fibrillation at time of return to work; Yes if: Anticoagulated adequately for at least 1 month; Anticoagulation monitored by at least monthly INR; Rate/rhythm control deemed adequate (Recommend assessment by cardiologist).	Annual

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

SUPRAVENTRICULAR TACHYCARDIAS (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 97

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Atrial Flutter	Same as for atrial fibrillation.	Same as for atrial fibrillation. Yes if: Isthmus ablation performed and at least 1 month after procedure; Arrhythmia successfully treated; Cleared by electrophysiologist.	Same as for atrial fibrillation. Annual
Multifocal Atrial Tachycardia	Often associated with comorbidities, such as lung disease, that may impair prognosis.	Yes if: Asymptomatic; Unless associated condition is disqualifying. No, if symptomatic. Yes if: Symptoms controlled and secondary cause is not exclusionary.	Annual Annual
Atrioventricular Nodal Reentrant Tachycardia (AVNRT) Atrioventricular Reentrant Tachycardia (AVRT) and Wolff-Parkinson-White (WPW) Syndrome Atrial Tachycardia Junctional Tachycardia	Prognosis generally excellent, but may rarely have syncope or symptoms of cerebral hypoperfusion. For those with WPW, pre-excitation presents risk for death or syncope if atrial fibrillation develops.	No if: Symptomatic; WPW with atrial fibrillation. Yes if: Asymptomatic; Treated and asymptomatic for at least 1 month and assessed and cleared by expert in cardiac arrhythmias.	Annual Recommend consultation with cardiologist.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

VALVE REPLACEMENT

2002 Cardiovascular Conference Report Recommendation Tables, Page 80

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION RECOMMENDATION	CERTIFICATION
Mechanical Valves		<p>Yes if: At least 3 months post-op; Asymptomatic; Cleared by cardiologist.</p> <p>No if: Symptomatic; LV dysfunction-EF <40%; Thromboembolic complication post procedure; Pulmonary hypertension; Unable to maintain adequate anticoagulation (based on monthly INR checks).</p>	Annual Recommendation evaluation by cardiologist.*
Pr	prosthetic valve dysfunction.	<p>No</p> <p>Yes if: Surgically corrected; At least 3 months post-op; Asymptomatic; Cleared by cardiologist.</p>	Annual Recommendation evaluation by cardiologist.*

* Role of annual echocardiography in stable patients is controversial.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

VALVE REPLACEMENT (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 81

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
	Atrial fibrillation.	Yes if: Anticoagulated adequately for at least 1 month and monitored by at least monthly INR, rate/rhythm control adequate; Cleared by cardiologist.	Annual
Biologic Prostheses	Anticoagulant therapy not necessary in patients in sinus rhythm (after initial 3 months), in absence of prior emboli or hypercoagulable state.	Yes if: At least 3 months post-op; Asymptomatic; None of above disqualifying criteria for mechanical valves; Cleared by cardiologist.	Annual Recommend evaluation by cardiologist.*

* Role of annual echocardiography in stable patients is controversial.

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

VENOUS DISEASE

2002 Cardiovascular Conference Report Recommendation Tables, Page 147

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Acute Deep Vein Thrombosis (DVT)		No, if symptoms. Yes if: No residual acute deep venous thrombosis; If on Coumadin: Regulated for at least 1 month; INR monitored at least monthly.	Annual
Superficial Phlebitis		Yes if: DVT ruled out; No other disqualifying cardiovascular disease.	Biennial
Pulmonary Embolus		No, if symptoms. Yes if: No pulmonary embolism for at least 3 months; On appropriate long-term treatment; If on Coumadin: Regulated for at least 1 month; INR monitored at least monthly; No other disqualifying cardiovascular disease.	Annual
Chronic Thrombotic Venous Disease		Yes, if no symptoms.	Biennial
Varicose veins		Yes, if no complications.	Biennial
Coumadin	Use of INR required.	Yes if: Stabilized for 1 month; INR monitored at least monthly.	Annual

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

VENTRICULAR ARRHYTHMIAS

2002 Cardiovascular Conference Report Recommendation Tables, Page 98

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Coronary Heart Disease (CHD)	<p>Sustained VT: Poor prognosis and high risk.</p> <p>NSVT, LVEF <0.40: Unfavorable prognosis.</p> <p>NSVT, LVEF ≥0.40: Generally considered to have good prognosis.</p>	<p>No</p> <p>No</p> <p>No, if symptomatic.</p> <p>Yes if: Asymptomatic; At least 1 month after drug or other therapy is successful; Cleared by cardiologist.</p>	<p>Annual Cardiology examination required.</p>
Dilated Cardiomyopathy	<p>NSVT (LVEF ≤0.40).</p> <p>Sustained VT, any LVEF.</p> <p>Syncope/near syncope, any LVEF: High risk.</p>	<p>No</p> <p>No</p> <p>No</p>	
Hypertrophic Cardiomyopathy	Variable but uncertain prognosis.		

Important Note: This print file was current as of “February 2009.” Check for more recent updates at http://nrcme.fmcsa.dot.gov/part_4_guide_ep.htm#lastup.htm.

VENTRICULAR ARRHYTHMIAS (Continued)

2002 Cardiovascular Conference Report Recommendation Tables, Page 99

DIAGNOSIS	PHYSIOLOGY/ FUNCTIONAL	CERTIFICATION	RECERTIFICATION
Right Ventricular Outflow VT	Favorable prognosis and low risk for syncope.	No, if symptomatic. Yes, if asymptomatic. Yes if: At least 1 month after drug or other therapy successful; Asymptomatic; Cleared by electrophysiologist.	Annual Recommend evaluation by cardiologist. Annual Evaluation by cardiologist required.
Idiopathic Left Ventricular VT	Favorable prognosis and low risk for syncope.	No, if symptomatic Yes, if asymptomatic. Yes if: At least 1 month after successful drug therapy or ablation; Cleared by electrophysiologist.	Annual Recommend evaluation by cardiologist. Annual Evaluation by cardiologist required.
Long QT Interval Syndrome	High risk for ventricular arrhythmic death.	No	
Brugada Syndrome	High risk for ventricular arrhythmic death.	No	

EF = ejection fraction

LV = left ventricular

NSVT = nonsustained ventricular tachycardia

VT = ventricular tachycardia

